Deciphera Pharmaceuticals LLC

97 articles with Deciphera Pharmaceuticals LLC

• Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/16/2019

  Data from four of the Company’s pipeline programs will be presented in poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 26-30, 2019 in Boston, MA.

• 

  BioSpace Movers & Shakers, Oct. 4

  10/4/2019

  Life science and pharma companies strengthen their leadership teams with this week's appointments.

• Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer

  10/2/2019

  Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer

• Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

  9/30/2019

  INVICTUS pivotal Phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors (GIST) in an oral session at the European Society for Medical Oncology (ESMO) 2019 Congress.

• Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference

  9/25/2019

  Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2 at 9:30 AM ET in New York City.

• Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress

  9/5/2019

  Deciphera Pharmaceuticals, Inc. announced that data from the Company’s INVICTUS pivotal Phase 3 study of ripretinib in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors has been selected as an oral presentation at the European Society for Medical Oncology 2019 Congress to be held September 27 – October 1, in Barcelona, Spain.

• Deciphera Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

  9/3/2019

  Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 1,621,621 shares of the Company’s common stock at a price of $37.00 per share before underwriting discounts.

• Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock

  8/19/2019

  Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering.

• 

  Clinical Catch-up for August 12-16

  8/19/2019

  As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.

• Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

  8/15/2019

  Deciphera Pharmaceuticals, Inc. announced the pricing of its previously announced registered underwritten public offering of 10,810,810 shares of its common stock at a price to the public of $37.00 per share.

• Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors

  8/13/2019

  Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST

• Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

  8/13/2019

  Deciphera Pharmaceuticals, Inc. announced positive top-line data from the INVICTUS pivotal Phase 3 clinical study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors.

• 

  Deciphera Soars on Positive Late-Stage Data in Gastrointestinal Stromal Tumors

  8/13/2019

  Deciphera’s stock jumped from Monday’s close of $19.95 to $44.40 this morning after the company showed ripretinib provided 6.3 months of progression-free survival compared to one month from placebo.

• Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

  8/13/2019

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock.

• Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results

  8/2/2019

  Deciphera Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2019 and provided an update on clinical and corporate developments.

• Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors

  7/8/2019

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors

• Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

  6/11/2019

  Deciphera Intends to Expand Ripretinib Development Program in Gastrointestinal Stromal Tumors (GIST) by Potentially Adding China Sites to the Ongoing Global Phase 3 INTRIGUE Study

• Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers

  6/10/2019

  Company to Host a Webcast on Tuesday, June 18, 2019 at 8 a.m. ET to Discuss Autophagy Inhibition and the Treatment of Mutant RAS Cancers

• Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference

  5/30/2019

  Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6 at 1:30 PM ET in New York City.

• Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference

  5/14/2019

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 20 at 9:00 AM ET at the Grand Hyatt New York.